CTRI/2024/05/066803尚未招募Unknown
Effectiveness of Ceftazidime Avibactum for treatment of Urosepsis and Intra abdominal Sepsis due to multidrug resistant gram negative bacteria :A retrospective observational study - NI
Pfizer PHARMACEUTICALS0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •WERE CONSECUTIVELY ADMITTED TO THE HOSPITAL BETWEEN 01 APRIL 2020 AND 31 MARCH 2023
- •HAD SUSPECTED OR DOCUMENTED MDR GRAM NEGATIVE INTRA ABDOMINAL SEPSIS OR UROSEPSIS
- •SEPSIS WAS DIAGNOSED ACCORDING TO THE THIRD INTERNATIONAL CONSENSUS DEFINITION FOR SEPSIS AND SEPTIC SHOCK
- •RECIEVED CEFTAZIDIME AVIBACTUM FOR ATLEAST 48 HOURS AS PER CLINICIAN DISCRETIO
排除标准
- •DOCUMENTED ACINETOBACTER INFECTION
- •RECIEVED CEFTADIZIME AVIBACTUM LESS THAN 48 HOURS
研究者
相似试验
进行中（未招募）
Unknown
Effectiveness of newer antibiotic combination named as ceftazidime avibactam for the treatment of blood infection due to Multi Drug Resistant gram negative bacteria.CTRI/2023/06/054356Medanta Institute of Education and Research
尚未招募
1 期
Comparing the efficacy of two antibiotic groups for gram negative sepsis in intensive care unitCTRI/2024/04/065863Trishita Saha
尚未招募
Unknown
Study to evaluate clinical effects of Polymyxins and Ceftazidime-Avibactum in critical patients and evaluate which group has better outcomes (CoP CAcRE)CTRI/2023/10/058761Research institution
尚未招募
3 期
The efficacy of ceftazidime on bacterial otitisIRCT20130427013136N6Babol University of Medical Sciences140
尚未招募
4 期
Impact of Rapid Diagnostics using a FilmArray Test and Early Targeted Treatment with Ceftazidime-Avibactam for Management of Severe Infections: A Comparative Study Against Standard CareCTRI/2024/04/066197ADVANCE ID